Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'

Br J Cancer. 2018 May;118(9):1276-1277. doi: 10.1038/s41416-018-0012-2. Epub 2018 Mar 22.

Matthew Dankner^{1

2}, April A N Rose³

¹ Goodman Cancer Research Centre, McGill University, Montreal, QC, Canada. matthew.dankner@mail.mcgill.ca.
² Department of Medicine, McGill University, Montreal, QC, Canada. matthew.dankner@mail.mcgill.ca.
³ Department of Medicine, Division of Medical Oncology, University of Toronto, Toronto, ON, Canada.

No abstract available

Publication types